D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans

Modern Pathology

Volumn 23, Issue 3, 2010, Pages 434-438

  Bandarchi, Bizhan ^a   Ma, Linglei ^b   Marginean, Celia ^c   Hafezi, Sara ^a   Zubovits, Judit ^a   Rasty, Golnar ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

D2 40; Dermatofibroma; Dermatofibrosarcoma protuberans

Indexed keywords

BLOOD CLOTTING FACTOR 13A; CD34 ANTIBODY; MONOCLONAL ANTIBODY D2-40; SIALOGLYCOPROTEIN;

ARTICLE; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH VESSEL ENDOTHELIUM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; DERMATOFIBROSARCOMA; DIAGNOSIS, DIFFERENTIAL; FACTOR XIIIA; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 77649270185     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.176     Document Type: Article

References (36)

1. Calonje E, Mentzel T, Fletcher CD. Cellular benign fibrous histiocytoma. Clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. Am J Surg Pathol 1994;18:668-676.
2. Vilanova JR, Flint A. The morphological variations of fibrous histiocytomas. J Cutan Pathol 1974;1:155-164.
3. Franquemont DW, Cooper PH, Shmookler BM, et al. Benign fibrous histiocytoma of the skin with potential for local recurrence: a tumor to be distinguished from dermatofibroma. Mod Pathol 1990;3:158-163.
4. McPeak CJ, Cruz T, Nicastri AD. Dermatofibrosarcoma protuberans: an analysis of 86 cases\five with metastasis. Ann Surg 1967;166:803-816.
5. Fletcher CDM, Evans BJ, Macartney JC, et al. Derma-tofibrosarcoma protuberans: a clinicopathological and immunohistochemical study with a review of the literature. Histopathology 1985;9:921-938.
6. Horenstein MG, Prieto VG, Nuckols JD, et al. Indeterminate fibrohistiocytic lesions of the skin. Is there a spectrum between dermatofibroma and dermatofibro-sarcoma protuberans? Am J Surg Pathol 2000;24:996-1003.
7. Zelger BG, Zelger B. Dermatofibroma. A clinico-pathologic classification scheme. Pathologe 1998;19: 412-419.
8. Aiba S, Tabata N, Ishii H, et al. Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumor expressing CD34. Br J Dermatol 1992;127:79-84.
9. Haycox CL, Odland PB, Olbricht SM, et al. Immuno-histochemical characterization of dermatofibrosarcoma protuberance with practical application for diagnosis and treatment. J Am Acad Dermatol 1997;37:438-444.
10. Kutzner H. Expression of human progenitor cell antigen CD34 (HPCA-I) distinguishes dermatofibrosar-coma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol 1993;28:613-617.
11. Cohen PR, Rapini RP, Farhood AI. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa. Am J Dermatopathol 1994;16:573-574.
12. Goldblum JR, Tuthill RJ. CD34 and factor XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma. Am J Dermatopathol 1997;19: 147-153.
13. Kahn HJ, Fekete E, From L. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuber-ans: comparison with CD34 and factor XIIIa. Hum Pathol 2001;32:50-56.
14. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumors. Br J Cancer 1999;80:569-578.
15. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcrip-tional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003;162: 575-586.
16. Fakunaga M. Expression of D2-40 in lymphatic endothelium of normal tissue and in vascular tumors. Histopathology 2005;46:396-402.
17. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
18. Roy S, Chu A, Trojanowski JQ, et al. D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastoma form renal cell carcinoma. Acta Neuropathol (Berl) 2005;109: 497-502.
19. Galambos C, Nodit L. Identification of lymphatic endothelium in pediatric vascular tumors and malformations. Pediatr Dev Pathol 2005;8:181-189.
20. Debelenko LV, Perez-Atayde AR, Mulliken JB, et al. D2-40 immunohistochemical analysis of pediatric vascular tumors reveal positivity in Kaposiform heman-gioendotheliomas. Mod Pathol 2005;18:1454-1460.
21. Rabban JT, Chen Y. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. Hum Pathol 2008;39:175-183.
22. Gomaa A, Yaar M, Bhawan J. Cutaneous immunor-eactivity of D2-40 antibody beyond the lymphatics. Am J Dermatopathol 2007;29:18-21.
23. Browling L, Parker A, Bailey D. D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumors from both metastatic clear cell renal cell carcinoma and pheochromocytoma. J Clin Pathol 2008;61:293-296.
24. Yu H, Gibson JA, Pinkus GS, et al. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumor. Am J Clin Pathol 2007;128:776-782.
25. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epitheloid malignant melanoma. Hum Pathol 2005;36: 372-380.
26. Lau SK, Weiss LM, Chu PG. D2-40 immunohistochem-istry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohisto-chemical study with KIT (VD117) and CD30. Mod Pathol 2007;20:320-325.
27. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinoma and germ cell tumors. Am J Pathol 2005;166:913-921.
28. Cerio R, Spaull J, Wilson Jones E. Histiocytoma Cutis: a tumor of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol 1989;120:197-206.
29. Cerio R, Spaull J, Oliver GF, et al. A study of factor IIIa and MAC387 immunolabeling in normal and pathological skin. Am J Dermatopathol 1990;12:221-233.
30. Allan AE, Tsou HC, Harrington A. Clonal origin of dermatofibrosarcoma protuberans. Invest Dermatol 1993;100:99-102.
31. Goncharuk V, Mulvaney M, Carlson JA. Bednár tumor associated with dermal melanocytosis: melanocytic colonization or neuroectodermal multidirectional differentiation? J Cutan Pathol 2003;30:147-151.
32. Nestle FO, Nickoloff BJ, Burg G. Dermatofibroma, an abortive immunoreactive process mediated by dermal dendritic cells? Dermatology 1995;190:265-268.
33. Aiba S, Tagami H. Phorbol 12-myristate 13-acetate can transform monocytes-derived dendritic cells to different cell types similar to those found in dermatofibro-ma. J Cutan Pathol 1998;25:65-71.
34. Dominguez-Malagon H, Valdez-Carrillo Mdel C, Cano-Valdez AM. Dermatofibroma and dermatofibrosarcoma protuberance: a comprehensive ultrastructural study. Ultrastructural Pathol 2006;30:283-291.
35. Marsee DK, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. Appl Immunohistochem Mol Morphol 2009;17:102-107.
36. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.